Shots:

• The BNT162b2 showed more than 90% efficacy in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis- conducted on Nov 8- 2020 from P-III clinical study
• The companies reported no serious safety concerns so far while safety and additional efficacy data continues to be collected. The company expect to seek US’ EUA in the third week of Nov’2020
• The companies will continue the clinical trial for final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints and plan to submit data from the full P-I trial for scientific peer-review publication

 ­ Ref: Pfizer | Image: LRT